Caveney Brian J sold $744K of LH

Caveney Brian J (EVP, Pres of BLS, CMO & CSO) sold 2,000 shares of LABCORP HOLDINGS INC. (LH) at $372.04 ($0.74M total) on 2026-11-10.

Original reporting
SEC EDGAR · Caveney Brian J
Published Nov 12, 2026, 12:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Bearish
medium confidence
Mentioned
$LH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHBearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership, which can be interpreted by investors as a negative signal, potentially prompting short‑term selling.

02

Market read

A modest insider sale by a senior executive, disclosed via Form 4, may cause slight downward pressure on LH but is unlikely to drive major market moves.

03

What to watch

No 10b5‑1 plan was used, indicating the sale was discretionary, which may carry more weight than automated sales.

Relevance 5/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings provide the first public disclosure of insider transactions, offering transparency into executive holdings.

Company-level read

Ticker impact

$LHBearishMedium confidence
Context

SEC Form 4 disclosed that EVP Brian Caveney sold 2,000 shares of Labcorp for $744,080, reducing his stake to 34,562 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell

Evidence & confidence

The sale is a modest $744k transaction by a senior executive; while not large enough to move the stock dramatically, it can trigger short‑term selling pressure.

Market effects

Minimal impact on the healthcare services sector; the filing is company‑specific.

U.S. market only; no broader regional effect.

Low; the transaction is a routine insider sale.

Counterpoint

The sale could be unrelated to confidence and merely a personal liquidity need, so the stock may remain unaffected.

Key entities

  • Labcorp Holdings Inc.

    U.S. clinical laboratory services provider (ticker LH).

  • Brian J. Caveney

    Executive Vice President, President of BLS, Chief Marketing Officer & Chief Strategy Officer at Labcorp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHHighAI 9/10

Labcorp completes $375M Millennium Health takeover

Labcorp completed its $375M acquisition of Millennium Health, including $245M upfront and up to $130M in milestone payments. The deal aims to enhance Labcorp's toxicology services and expand its geographic reach. Millennium specializes in drug testing, complementing Labcorp's existing offerings. Labcorp CEO Adam Schechter highlighted the strategic fit and growth potential during an earnings call.

$LHMed

Labcorp Finalizes Acquisition of Millennium Health to Expand Toxicology Testing

Labcorp has completed its acquisition of Millennium Health, a specialty lab focused on drug testing and surveillance. The deal aims to expand Labcorp's toxicology testing capabilities nationwide, providing insights for treating chronic pain, substance use disorders, and mental health conditions. Labcorp expects to integrate Millennium's expertise with its own network and digital solutions to improve patient care.

$OPKMed

OPKO Health Inc (OPK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 16% as LabCorp

OPKO Health Inc (OPK) reported Q3 2026 revenue growth of 16% YoY, driven by product revenue and strong performance from key products. The company expects to receive $722M in cash from the LabCorp transaction, plus up to $150M in royalties. OPK strengthened its balance sheet with $125M in financing and ended the quarter with $403.2M in cash. The company repurchased 7.2M shares for $10.6M.